» Articles » PMID: 25341640

Fetal Exposure to HIV-1 Alters Chemokine Receptor Expression by CD4+T Cells and Increases Susceptibility to HIV-1

Overview
Journal Sci Rep
Specialty Science
Date 2014 Oct 25
PMID 25341640
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Absolute numbers of lymphocytes are decreased in uninfected infants born to HIV-1-infected women (HIV-1-exposed). Although the exact mechanism is unknown, fetal exposure to maternal HIV-1-infection could prime the immune system and affect T cell trafficking. We compared the expression of chemokine receptors on cord blood CD4(+) T cells from HIV-1-exposed children and healthy controls. At baseline CD4(+) T cells had a largely naïve phenotype. However, stimulation with cytokines resulted in an upregulation of inflammatory response-related chemokine receptors on CD4(+) T cells, with HIV-1-exposed infants having a significantly higher frequency of CD4(+) T cells expressing, in particularly Th2 associated chemokine receptors (CCR3 p < 0.01, CCR8 p = 0.03). Numbers of naive CCR7(+) CD4(+) T cells were reduced (p = 0.01) in HIV-1-exposed infants. We further assessed whether the inflammatory phenotype was associated with susceptibility to HIV-1 and detected higher levels of p24 upon in in vitro infection of stimulated CD4(+) T cells of HIV-1-exposed infants. In summary, fetal exposure to HIV-1 primes the immune system in the infant leading to an enhanced immune activation and altered T cell homing, with potential ramifications regarding T cell responses and the acquisition of HIV-1 as an infant.

Citing Articles

Maternal immunity shapes biomarkers of germinal center development in HIV-exposed uninfected infants.

Yin L, Venturi G, Barfield R, Fischer B, Kim-Chang J, Chan C Front Immunol. 2024; 15:1443886.

PMID: 39328414 PMC: 11424517. DOI: 10.3389/fimmu.2024.1443886.


Prenatal exposure to maternal disadvantage-related inflammatory biomarkers: associations with neonatal white matter microstructure.

Sanders A, Tirado B, Seider N, Triplett R, Lean R, Neil J Transl Psychiatry. 2024; 14(1):72.

PMID: 38307841 PMC: 10837200. DOI: 10.1038/s41398-024-02782-6.


Impact of chronic toxoplasmosis in pregnancy: association between maternal seropositivity for Toxoplasma gondii IgG antibodies and fetal growth restriction.

Martinez V, Dos Santos N, Bah H, Gomes Junior E, Costa D, Menezes-Filho J Parasitol Res. 2023; 123(1):25.

PMID: 38072839 DOI: 10.1007/s00436-023-08068-y.


Maternal acellular pertussis vaccination in mice impairs cellular immunity to Bordetella pertussis infection in offspring.

Dubois V, Chatagnon J, Depessemier M, Locht C JCI Insight. 2023; 8(18).

PMID: 37581930 PMC: 10561720. DOI: 10.1172/jci.insight.167210.


Balance between maternal antiviral response and placental transfer of protection in gestational SARS-CoV-2 infection.

Goncalves J, Melro M, Alenquer M, Araujo C, Castro-Neves J, Amaral-Silva D JCI Insight. 2023; 8(17).

PMID: 37490342 PMC: 10544212. DOI: 10.1172/jci.insight.167140.


References
1.
Todd B, Pope J, Georghiou P . Interleukin-2 enhances production in 24 hours of infectious human immunodeficiency virus type 1 in vitro by naturally infected mononuclear cells from seropositive donors. Arch Virol. 1991; 121(1-4):227-32. DOI: 10.1007/BF01316757. View

2.
Gompels U, Larke N, Sanz-Ramos M, Bates M, Musonda K, Manno D . Human cytomegalovirus infant infection adversely affects growth and development in maternally HIV-exposed and unexposed infants in Zambia. Clin Infect Dis. 2012; 54(3):434-42. PMC: 3258277. DOI: 10.1093/cid/cir837. View

3.
Chenadec J, Mayaux M, Guihenneuc-Jouyaux C, Blanche S . Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS. 2003; 17(14):2053-61. DOI: 10.1097/00002030-200309260-00006. View

4.
Bunders M, Pembrey L, Kuijpers T, Newell M . Evidence of impact of maternal HIV infection on immunoglobulin levels in HIV-exposed uninfected children. AIDS Res Hum Retroviruses. 2010; 26(9):967-75. DOI: 10.1089/aid.2009.0241. View

5.
. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005; 40(3):458-65. DOI: 10.1086/427287. View